Gane E. Safety and Efficacy at 1 year after Switching from Tenofovir Disoproxil Fumurate to Tenofovir Alafenamide in Chronic HBV Patients with Risk Factors for TDF Use. PS-156.
Silencing van het hepatitis B-virus S-gen door CRISPR‐gemedieerde base editing
feb 2020 | Hepatitis, Hepatologie, Virale infecties